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Does anti-Müllerian hormone predict change in menopausal symptoms 26 
following risk-reducing salpingo-oophorectomy? A prospective 27 
observational study 28 
Objectives 29 
The aim of this study was to investigate whether serum Anti Müllerian hormone (AMH) 30 
predict symptom burden after risk-reducing salpingo-oophorectomy (RRSO) in order to 31 
individualize counselling. 32 
Methods 33 
Patient-reported menopausal symptoms, sexual functioning and psychological distress 34 
(depression and anxiety) were assessed one day before (T0), and six weeks (T1) and seven 35 
months (T2) after RRSO. AMH was assessed before RRSO. Multivariable regression analysis 36 
was used to investigate the association between AMH and short-term and long-term change in 37 
symptom burden following RRSO. 38 
Results  39 
91 premenopausal women at high risk of ovarian cancer were included. Pre-surgical AMH 40 
was not related significantly to change in symptoms post-RRSO. As secondary outcome we 41 
found that regular menses before RRSO was associated specifically with long-term increase 42 
in hot flushes (sr 0.40, p=0.001; total R2 0.171) and depression (sr 0.29 p=0.012; total R2 43 
0.132). Earlier receipt of chemotherapy was associated with long-term improvement in sexual 44 
functioning (sr 0.24, p=0.041; total R2 0.348).  45 
Conclusions  46 
In this cohort, AMH was not a significant predictor of change in symptoms following RRSO. 47 
Regular menses prior to RRSO and earlier receipt of chemotherapy were significantly, but 48 
relatively weakly associated with changes in outcomes six weeks and/or seven months after 49 
RRSO.  50 
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Introduction 53 
Approximately 10% of all ovarian carcinomas (OC) are due to inherited predisposition[1]. 54 
Ovarian cancer screening is not effective in detecting OC at an earlier stage or in improving 55 
prognosis[2]. Therefore, risk-reducing salpingo-oophorectomy (RRSO) is recommended to 56 
lower the risk of OC[3]. After RRSO, the risk of OC is reduced by 80%-96%[4, 5, 6]. The 57 
recommended age for RRSO after childbearing in BRCA1 carriers is between 35-40 years, 58 
and in BRCA2 carriers between 40-45 years. Women from a hereditary breast and ovarian 59 
cancer (HBOC) family are advised to undergo RRSO after childbearing is completed, but no 60 
specific age is given[4, 6].  61 
A major side-effect of RRSO in premenopausal women is the immediate onset of 62 
menopause, accompanied by an increase in non-cancer related morbidity, including a range of 63 
endocrine symptoms, sexual symptoms, mood disturbance, as well as an increased risk of 64 
cardiovascular disease and osteoporosis[7, 8, 9]. However, there is a wide variability in 65 
symptom prevalence and severity, and it is not clear why some women experience more 66 
severe symptoms than others. Understanding what factors influence the severity of symptoms 67 
following RRSO is important for providing appropriate patient counselling. 68 
To the best of our knowledge, no studies, to date, have investigated predictors of 69 
menopausal symptom severity following RRSO. There have been a few studies of predictors 70 
of menopausal symptoms in healthy, postmenopausal women. One cross-sectional study 71 
found that the severity of menopausal symptoms was significantly influenced by life 72 
conditions and events, but not by hormonal changes[10]. Nonetheless, the authors stated that 73 
the exact influence of hormones should be investigated in future studies. In another study, 74 
these same investigators found that more perceived self-control on hot flushes and night 75 
sweats was associated with less severe vasomotor symptoms[11]. A prospective study among 76 
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women with moderate to severe hot flushes and night sweats reported that negative beliefs 77 
about night sweats and sleep were the strongest predictors of concordance between objective 78 
and subjective measures of these symptoms[12]. All these studies focused either on lifestyle 79 
or psychological variables; none included potential biologic predictors of symptom severity.  80 
Previous work has shown that release of anti-Müllerian hormone (AMH) from the 81 
granulosa cells of antral follicles leads to measurable serum levels. These concentrations are 82 
strongly associated with the number of developing follicles in the ovaries[13]. Because AMH 83 
is relatively stable through the menstrual cycle, the measurement of serum AMH has a range 84 
of clinical applications, including estimating ovarian reserve and predicting age of natural 85 
menopause[14, 15, 16]. A decrease in serum AMH has been found in young women after 86 
chemotherapy or anti-hormonal therapy for cancer[17], and it has been suggested that post-87 
chemotherapy AMH levels also predict residual ovarian function[18]. Therefore, AMH is 88 
considered to be a marker for the process of ovarian ageing[19]. The ‘younger ovary’ pattern 89 
has higher AMH levels than the ‘aging ovary’ pattern, suggesting diminishing ovarian reserve 90 
as a function of age [20]. Given this background, we hypothesized that the higher the AMH 91 
levels pre-RRSO, the more severe the menopausal symptoms post-RRSO. 92 
In the present study, we investigated whether higher pre-surgical AMH levels are 93 
related to: (1)the severity of post-RRSO menopausal symptoms, in general, and the perceived 94 
burden of hot flushes and night sweats, in particular; (2)sexual functioning; and 95 
(3)psychological distress (depression and anxiety). In addition to AMH levels, we 96 
investigated the possible association between post-RRSO symptoms and a range of 97 
sociodemographic and clinical variables. If successful in identifying relevant predictors of 98 
symptom severity, this information could be used in counselling pre-treatment symptom 99 
experience.  100 
Methods 101 
Research setting and study sample 102 
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This prospective, observational, multicenter study was carried out at The Netherlands Cancer 103 
Institute and the Leiden University Medical Center in the Netherlands. The institutional 104 
review boards of both centers approved the study. Participants were included from November 105 
2006 until April 2012. Patients with a BRCA1/2 mutation or women from a HBOC family 106 
with an estimated risk higher than 10% undergoing RRSO, were eligible[21]. Women were 107 
invited to participate at the outpatient clinic by the gynecologist when they decided to 108 
undergo an RRSO. 109 
Inclusion criteria were being premenopausal at time of RRSO and understanding the 110 
Dutch language. Women were excluded from the study if they had cancer at the time of 111 
RRSO. Premenopausal status was defined as having one or more menstrual periods over the 112 
last twelve months or using (hormonal) contraception. If a woman did not have menstrual 113 
periods due to a hysterectomy, we took age as a proxy indicator of menopausal status. 114 
Women younger than 51 years were considered premenopausal and women aged 51 years or 115 
older were considered postmenopausal. In the Netherlands, most women are postmenopausal 116 
by the age of 51 [22].  117 
Women were invited to participate in the study by their gynecologist at the time they 118 
decided to undergo a RRSO. A blood sample was obtained within 24 hours before the RRSO 119 
was performed. Women were asked to complete questionnaires at three time points: one day 120 
before RRSO (T0), and six weeks (T1) and seven months following surgery (T2).  All 121 
participants provided written informed consent. 122 
Measures 123 
The respondents’ age, education, employment status, relationship status, parity, body mass 124 
index (BMI), comorbidities, mutation status, regular menses, history of breast cancer, 125 
previous breast cancer treatments and current menopausal status were obtained by self-report. 126 
Women were asked if they had regular menses during the past 3 months. If they responded 127 
negatively to this question, the reason why the menses was irregular was asked. AMH level 128 
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was measured in the serum obtained within 24 hours before RRSO with an enzyme-linked 129 
immunosorbent assay (ELISA), 2nd generation (Beckmann Coulter, Brea, California USA). 130 
Expected values for premenopausal women range from undetectable (<0.10 µg/l) to 10.6 µg/l 131 
(2.5%-97.5%).  132 
The Functional Assessment of Cancer-Therapy-Endocrine Symptoms (FACT-ES) was 133 
used to assess endocrine symptoms commonly experienced by women after natural, 134 
surgically-induced, or medically-induced menopause. The FACT-ES was used in this 135 
population before [23, 24] and a validation study showed that the FACT-ES has acceptable 136 
validity reliability and is sensitive to clinically significant change [25]. The FACT-ES 137 
consists of 18 items that address a range of menopausal symptoms. Occurrence of each 138 
symptom in the past four weeks is scored on a 5-point scale, ranging from ‘not at all’ to ‘very 139 
much’. Item scores are summed to obtain a total score (range: 0 – 72), with lower values 140 
indicating more menopausal symptoms [25].   141 
We also used the Hot Flush Rating Scale (HFRS) to specifically assess the perceived 142 
burden of hot flushes and night sweats over the past week. The HFRS problem rating score is 143 
the mean of three 1 to 10 numerical scales assessing the extent to which hot flushes and night 144 
sweats were problematic, distressing and cause interference in daily life. Higher scores 145 
indicate more problematic symptoms [26][25][24]. 146 
We assessed sexual functioning with the Sexual Functioning Questionnaire (SFQ).  147 
The SFQ consists of 7 domains: desire (6-items); arousal-sensation (4 items); arousal-148 
lubrication (2 items); orgasm (3 items); enjoyment (6 items); pain (3 items); and partner 149 
relationship (2 items). Higher scores indicate better sexual functioning[27].  150 
Finally, we employed the Hospital Anxiety and Depression Scale (HADS) to assess 151 
psychological distress. The HADS has two 7-item subscales, one for anxiety and one for 152 
depression. A score of between 8 and 10 on the total scale represents a subclinical level of 153 
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anxiety or depression. The higher the scores the more clinically relevant the anxiety or 154 
depression[28].  155 
Statistical Analysis  156 
Scores of the FACT-ES, HFRS, SFQ, the HADS anxiety and the HADS depression, were 157 
calculated according to published scoring algorithms. If 50% or fewer of the items were 158 
missing from a multi-item scale, the average of the remaining items was used to calculate the 159 
scale score. We also examined the pattern of missing questionnaires at the three time points, 160 
and whether the characteristics of respondents with missing questionnaires differed from 161 
those with no missing questionnaires.  162 
Due to the non-normal distribution of AMH and the substantial number of AMH 163 
levels below the limit of detection, we categorized this measure in three groups: (1) less or 164 
equal to 0.10 µg/l; (2) more than 0.10 µg/l and less or equal to 1.0 µg/l; and (3) more than 1.0 165 
µg/l.  166 
Continuous data are presented as means and standard deviations (SD); discrete data as 167 
counts and percentage. We used Pearson correlations to examine the association between two 168 
continuous variables, Student’s t-test for dichotomous and continuous data, and one-way 169 
analysis of variance for categorical and continuous data.  170 
 We used bivariate and multivariable linear regression analysis to investigate potential 171 
predictors (pre-surgical AMH levels, age, education, employment status, relationship status, 172 
parity, BMI, comorbidities, mutation status, regular menses, history of breast cancer, potential 173 
received breast cancer treatments) of changes in: (1) menopausal symptoms, in general, and in 174 
hot flushes and night sweats, in particular; (2) sexuality, and (3) psychological distress. 175 
Change scores were calculated from baseline to six weeks (T0-T1; short-term) and seven 176 
months (T0-T2; long-term) post-RRSO follow-up. We assessed possible multicollinearity by 177 
inspecting the models and calculating the variance inflation factor (VIF). In case of a VIF>10, 178 
we took into account the importance of the variables and excluded the variable which doesn’t 179 
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seem essential to the model. Bivariate analyses with p<0.10 were conducted to select potential 180 
multivariable predictors. Because serum AMH level was the variable of primary interest, we 181 
included it in the multivariable model regardless of whether it was significant at the bivariate 182 
level.  183 
We considered p<0.05 significant in the multivariable analysis. The adjusted R2 is the 184 
proportion of variance in the dependent variable that is explained by the variables included in 185 
the model and the total R2 is the total amount of variance explained by the independent 186 
variables in the regression model. The semipartial (sr) correlation is the variance explained in 187 
the dependent variable by a single independent variable.  188 
All statistical analyses were carried out using Stata 12 (StataCorp LLC).  With power 189 
set at 80% and alpha set at 0.05, a sample of 58 subjects is sufficient to conduct a regression 190 
analysis with five predictors, assuming that AMH levels account for 11% or more variability 191 
and the complete model would account for 21% or more of the variability in the outcomes. 192 
Results 193 
Population  194 
Women were recruited into the study between November 2006 and April 2012. In total, 124 195 
premenopausal women were invited to participate. Of these 124 women, three women 196 
ultimately decided not to undergo an RRSO, six transitioned into post-menopause between 197 
the invitation and study inclusion, one was diagnosed with OC, four anticipated logistical 198 
problems, two did not provide informed consent, and 17 declined without providing a reason.  199 
The background characteristics of the 91women who participated in the study are 200 
described in Table 1. The mean (±SD) age of the participants was 43 (±5) years, 87% were in 201 
a relationship (married/cohabitating), 71% had advanced level education, and 85% was 202 
employed. Eighty-five percent of the women had a proven BRCA 1/2 mutation, and 28% had 203 
a history of breast cancer (BC). At the pre-surgical assessment, half of the women reported 204 
having a regular menses, i.e. with regular intervals between 3-6 weeks. The other half of the 205 
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women had irregular menses or no menses due to various reasons such as hysterectomy, 206 
chemotherapy, hormonal anti-conception or the reason was unknown. Thirty-six women 207 
(40%) had AMH levels less or equal to 0.10 µg/l, 32 women (35%) had an AMH level that 208 
was more than 0.10 µg/l and less or equal to 1.0 µg/l (35%), and 23 women (25%) had an 209 
AMH level greater than 1.0 µg/l (25%).  210 
With the exception of the SFQ, patient reported outcome (PRO) assessments were 211 
completed by 86 of the 91 women at baseline, 82 women at six weeks, and 79 women at 212 
seven months. The SFQ was completed by 84 women at baseline, 81 women at six weeks, 213 
and 58 women at seven months. We found no significant differences in baseline 214 
sociodemographic and clinical characteristics or in baseline and follow-up patient-reported 215 
menopausal, sexual, depression and anxiety symptoms between women who had completed 216 
all assessments and those who had missing assessments on one or both of the follow-up 217 
assessments (data not shown). 218 
 The extended table 2 (see online appendix) shows the results from the bivariate 219 
analyses that were conducted to identify potential predictors of change from baseline to 220 
follow-up in symptom outcomes. Those variables for which the association with symptom 221 
outcomes was significant at the 0.10 level or lower were selected for inclusion in the 222 
subsequent multivariable analyses (extended table 3).  223 
Multivariable predictors of symptom outcomes at six weeks and seven months post RRSO 224 
At the multivariable level (Table 3), AMH levels were not associated significantly with any of 225 
the symptom outcomes. When examining the multicollinearity in the SFQ model at six weeks, 226 
BC and comorbidity were highly correlated (IF= 10.01). Given this multicollinearity, we 227 
decided to include BC in the final model, because we were more interested in this outcome as 228 
all women in our study were at risk of BC. Having a relationship (sr -0.22, p=0.046) and 229 
having regular menses before RRSO (sr-0.27, p=0.015) were associated with a short-term 230 
increase in menopausal symptoms (FACT-ES) (total R2 = 0.143). There were no differences 231 
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in the FACT-ES scores at baseline or at six-week follow-up between single women and 232 
women in a relationship when excluding the items on sexuality (items 7, 8 and 9). No 233 
variables were associated significantly with short-term change in the FACT-ES, HFRS, SFQ 234 
or HADS.  235 
In the model for change in SFQ at seven months, tamoxifen was the only hormonal 236 
therapy which was reported to have been used. For this reason, we excluded tamoxifen use as 237 
a potential predictor in the model. Having regular menses pre-surgery was independently 238 
associated with a long-term increase in hot flushes (HFRS: sr 0.40, total R2 = 0.171, p=0.001) 239 
and in depression (HADS depression: sr 0.29, total R2 = 0.132, p=0.012). Having received 240 
chemotherapy (sr 0.24, total R2 = 0.348, p=0.041) for the treatment of BC prior to RRSO was 241 
independently associated with a long-term improvement in sexual functioning (SFQ). We 242 
explored this latter finding further by examining the differences in the baseline SFQ scores 243 
between women who underwent chemotherapy in the past and women who did not. We found 244 
that, at baseline, women who had received chemotherapy in the past showed significantly 245 
worse sexual functioning (mean= 90, SD= 35) than women who did not (mean= 113, SD= 25, 246 
p=0.005). This suggests that there was more room for improvement in sexual functioning in 247 
women who had received chemotherapy in the past. None of the variables investigated were 248 
independently associated with long-term change in FACT-ES and anxiety as measured by the 249 
HADS.  250 
Discussion 251 
This is the first study to investigate prospectively the potential value of AMH in 252 
predicting the change in postmenopausal symptoms after RRSO. Because previous 253 
studies reported that AMH could be a marker for the process of ovarian ageing [18, 19, 254 
29], we hypothesized that AMH might predict change in menopausal symptoms: the 255 
higher the AMH levels pre-RRSO the worse the menopausal symptoms post-RRSO. 256 
This proved not to be the case. A systematic review concluded that AMH is the most 257 
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promising currently available biomarker for predicting age at natural menopause[30]. 258 
However, it does not predict menopausal transition very well at the extremes of the age 259 
range (i.e. very young or very old women) since it has wide prediction intervals[30] and 260 
the predictive value is less strong with increasing age and becomes less reliable the 261 
closer to menopause[31]. Because the mean age in our sample was 43.0 years, which is 262 
relatively late in the reproductive age-range, AMH levels could be less reliable. It may 263 
be that self-reported regular menses is a better predictor of menopause, and that could 264 
be the reason that we did not find any association between the AMH levels and the 265 
patients’ self-reported symptom levels.  266 
We found that women with regular menses before surgery reported more 267 
endocrine symptoms at six weeks after RRSO and more hot flushes and depressive 268 
symptoms at seven months after RRSO. Women with irregular menses are more likely 269 
to already be in a transition phase to menopause. It has been hypothesized that the 270 
immediate onset of menopause after oophorectomy results in more severe complaints in 271 
women who still have regular menses pre-RRSO[32]. This is supported by our results in 272 
which we found a greater increase in endocrine and depressive symptoms after RRSO in 273 
women with regular pre-surgical menses as compared to those women with irregular 274 
menses.   275 
 Having a relationship was weakly associated with an increase in menopausal 276 
symptoms six weeks after RRSO. An explanation could be that some of the items in the 277 
FACTES are more focused on sexuality, such that they might be more relevant for 278 
married/cohabitating women than single women. And indeed, analyzing the FACT-ES 279 
data without the sexual questions did not yield a significant difference in the prevalence 280 
of menopausal symptoms between women with a relationship and single women any 281 
more. Unexpectedly, we found an improvement in sexual functioning in women who 282 
underwent earlier chemotherapy after RRSO. Both chemotherapy and RRSO are known 283 
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for their detrimental effect on ovarian function. Therefore, the effect of RRSO could be 284 
less severe in this group of women, because the ovarian function was already negatively 285 
altered by the BC treatment in the past. This is supported by the observed difference in 286 
baseline SFQ scores.   287 
A limitation of our study is the relatively short follow-up, because differences in 288 
patient-reported outcomes might continue to change over a longer period of time. Loss 289 
to follow-up for some outcomes is a study limitation and the multiple comparisons 290 
could lead to the probability of change findings. Also, there is a minor possibility of 291 
incorrectly identifying menopausal status due to hysterectomy or use of hormonal 292 
contraceptives. In addition, hormonal contraception could decrease AMH levels by 30% 293 
[33]. Because these limitations are subject to such a small group of women, we do not 294 
think they would change the outcomes. The strengths of our study include its 295 
prospective design, the use of validated questionnaires to assess symptoms, and the 296 
relatively large sample size for this specific group of women.   297 
In conclusion, our findings indicate that AMH serum levels do not predict 298 
changes in endocrine and sexual symptoms or in psychological distress following 299 
RRSO in women at increased risk of OC. Having regular menses prior to RRSO and, to 300 
a lesser degree, having a relationship were weakly associated with severe menopausal 301 
symptoms after surgery. We suggest that further research focusses on individualizing 302 
counseling, not with predictive values, but more in communicative tools such as 303 
decision aids. In this way, more women know what to expect after RRSO: this may 304 
lower the experienced symptoms and enables women to already think about symptom 305 
lowering strategies such as hormone replacement therapy. 306 
The authors report no conflicts of interest.   307 
This research did not receive any specific grant from funding agencies in the public, commercial, or 308 
not-for-profit sectors. 309 
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Table 1. Demographics of 91 premenopausal women* 
Variables N (%) 
Age (Years)  
    Mean (SD) 43.0 (4.8) 
Relationship status   
    Married/cohabitating 79 (87%) 
    Single/divorced 12 (13%) 
Education   
    Primary school to middle level high school 26 (29%) 
    Advanced vocational/ university 65 (71%) 
Employment status   
Full-time or part-time job 77 (85%) 
Housewife 8 (9%) 
Other 6 (7%) 
Children 80 (88%) 
BMI (kg/m2)  
    Mean (SD) 24.2 (3.4) 
Comorbidities (%) 31 (34%) 
Gene mutation   
    Negative 8 (9%) 
    Unknown 6 (7%) 
    BRCA1 49 (54%) 
    BRCA2 28 (31%) 
Oral contraceptive 9 (10%) 
Regular menses 46 (51%) 
History of BC 25 (28%) 
   Radiotherapy for BC 14 (15%) 
   Chemotherapy for BC 15 (17%) 
   Hormonal therapy for BC 3 (3%) 
   Tamoxifen 4 (4%) 
AMH level µg/L   
    median (IQR) 0.34 (≤0.10-1.01) 
    ≤0.10 µg/L 36 (40%) 
    0.10-1.00 µg/L 32 (35%) 
    ≥1.00 µg/L 23 (25%) 
Abbreviations: SD standard deviation; BC breast cancer; AMH Anti-Müllerian hormone; IQR 
inter quartile range.    
*Four women younger than 51 years who underwent hysterectomy were identified as 
premenopausal women 
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Table 2. Bivariate analysis of factors associated with complaints after 6 weeks (T1) and 7 months (T2)             
  Change in FACT-ES Change in HFRS Change in SFQ Change in HADS depression Change in HADS anxiety 
  6 weeks 7 months 6 weeks 7 months 6 weeks 7 months 6 weeks 7 months 6 weeks 7 months 
Variables   P value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value 
AMH level µg/l                                         
     (≤0.10) 
(N=36) 
-3 
±11 0.804 -3 ±9 0.161 1 ±2 0.643 1 ±2 0.798 
-11 
±30 0.202 -9 ±37 0.579 2 ±4 0.301 1 ±3 0.161 0 ±3 0.513 0 ±3 0.052 
     (0.10-1.00) 
(N=32) 
-4 
±10   -5 ±9   1 ±1   1 ±1   
-25 
±38   
-19 
±34   0 ±2   0 ±1   -1 ±5   -1 ±3   
     (≥1.00) 
(N=23) 
-5 
±11   -8 ±9   1 ±2   1 ±1   
-29 
±33   
-17 
±29   0 ±5   2 ±4   -1 ±4   0 ±3   
Pearson correlation indicated by r; bold indicates P<0.10; continuous variables as mean (±standard deviation); discrete variables as number (percentage). Abbreviations: SD 
standard deviation; BC breast cancer; AMH Anti-Müllerian hormone; SFQ sexual functioning questionnaire; HADS hospital anxiety and depression scale; HFRS hot flush 
rating scale; FACT-ES functional assessment of cancer therapy – endocrine symptoms 
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Table 3 Multivariable analysis at six weeks and seven months 
Table 3 Complete mulitvariable analysis of factors associated with dependent variables  
Change at 6 weeks 
Regression 
coefficient (β) 
(95% CI) 
Standard 
error P value 
Semipartial correlation  Total R2 Change at 7 months 
Regression 
coefficient (β) 
(95% CI) 
Standard 
error P value 
Semipartial correlation  Total R2 
FACT-ES        0.143 FACT-ES        0.148 
AMH ≤0.10 µg/L ref         AMH ≤0.10 µg/L ref         
AMH 0.10-1.00 µg/L 1 (-4 to 7) 3 0.622 0.05   AMH 0.10-1.00 µg/L -1 (-5 to 4) 2 0.786 -0.03   
AMH ≥1.00 µg/L 0.4 (-6 to 7) 3 0.885 0.02   AMH ≥1.00 µg/L -3 (-8 to 2) 3 0.275 -0.12   
HFRS         0.06 HFRS         0.171 
AMH ≤0.10 µg/L ref        AMH ≤0.10 µg/L ref         
AMH 0.10-1.00 µg/L -0.5 (-1.3 to 0.4) 0.4 0.299 -0.12  AMH 0.10-1.00 µg/L -0.5 (-1.4 to 0.3) 0.4 0.207 -0.15   
AMH ≥1.00 µg/L -0.3 (-1.2 to 0.7) 0.5 0.591 -0.06  AMH ≥1.00 µg/L -0.9 (-1.9 to 0.0) 0.5 0.057 -0.22   
SFQ         0.219 SFQ         0.348 
AMH ≤0.10 µg/L ref         AMH ≤0.10 µg/L ref         
AMH 0.10-1.00 µg/L -11 (-32 to 10) 10 0.278 -0.14   AMH 0.10-1.00 µg/L -9 (-29 to 12) 10 0.406 -0.10   
AMH ≥1.00 µg/L -16 (-42 to 10) 13 0.229 -0.15   AMH ≥1.00 µg/L -7 (-32 to 18) 12 0.585 -0.06   
HADS Depression         0.078 HADS Depression         0.132 
AMH ≤0.10 µg/L ref         AMH ≤0.10 µg/L ref        
AMH 0.10-1.00 µg/L -1.4 (-3 to 0.3) 1 0.107 -0.18   AMH 0.10-1.00 µg/L -1.3 (-3 to 0.2) 1 0.094 -0.19   
AMH ≥1.00 µg/L -1.1 (-3 to 0.8) 1 0.251 -0.13   AMH ≥1.00 µg/L 0.3 (-1.4 to 2.0) 1 0.730 0.04   
HADS Anxiety         0.092 HADS Anxiety     0.080 
AMH ≤0.10 µg/L ref        AMH ≤0.10 µg/L ref         
AMH 0.10-1.00 µg/L -0.8 (-3 to 1) 1 0.459 -0.08  AMH 0.10-1.00 µg/L -1.5 (-3 to 0.1) 1 0.060 -0.22   
AMH ≥1.00 µg/L -0.4 ('-3 to 2) 1 0.755 -0.04   AMH ≥1.00 µg/L 0.4 (-1.3 to 2.2) 1 0.618 0.06   
Bold indicates statistical significance, P < 0.05. CI = Confidence interval, SD = standard deviation, SFQ = sexual functioning questionnaire, HADS = hospital anxiety and 
depression scale, HFRS = hot flush rating scale, FACT-ES = functional assessment cancer treat ment - endocrine symptoms, AMH = Anti-Müllerian hormone, BC = breast 
cancer 
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Supplemental online material  
Extended bivariate and multivariable analysis  
Table 2. Extended bivariate analysis of factors associated with complaints after 6 weeks (T1) and 7 months (T2)             
  Change in FACT-ES Change in HFRS Change in SFQ Change in HADS depression Change in HADS anxiety 
  6 weeks 7 months 6 weeks 7 months 6 weeks 7 months 6 weeks 7 months 6 weeks 7 months 
Variables   P value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value   
P 
value 
Age (yrs) r 0.05 0.676 r 0.02 0.834 r 0.07 0.548 r 0.13 0.271 r -0.13 0.324 r -0.22  0.094 r 0.08  0.516 r 0.11 0.347 r -0.03 0.803 
r -
0.12  0.289 
Marital status                                         
Married/living together -4.7 ±10 0.100 
-6.0 
±9 0.096 
0.9 
±2 0.783 
1.1 
±2 0.813 
-18 
±34  0.306 
-12 
±32 0.046 
0.7 
±3 0.076 1.0 ±3 0.741 
-0.25 
±4  0.070 
-0.3 
±3 0.261 
Single/divorced 0.6 ±12   
-1.1 
±10   
1.1 
±1   
1.2 
±1   
-35 
±36    
-43 
±40   
-1.3 
±6   1.2 ±4   -2 ±3   
-1.4 
±3   
Education                                         
Primary school to middle 
level high school 
-4.0 
±7 0.945 
-5.8 
±6 0.716 
1.2 
±1 0.448 
1.1 
±1 0.913 
-31 
±34 0.096 
-21 
±25 0.414 
0.3 
±2 0.776 0.6 ±2 0.458 
-0.7 
±5 0.826 
-0.5 
±3 0.899 
Advanced vocational/ 
university 
-3.8 
±11   
5.0 
±10   
0.8 
±2   
1.1 
±2   
-15 
±33   
-12 
±37   
0.5 
±4   1.2 ±3   
-0.5 
±3   
-0.4 
±3   
Employment                                         
Full-time or part-time job -4.3 ±9 0.040 
-5.1 
±9 0.641 
1.0 
±2 0.069 
1.1 
±2 0.629 
-21 
±34 0.820 
-17 
±33 0.070 
0.4 
±3 0.751 0.9 ±3 0.636 
-0.5 
±4 0.783 
-0.4 
±3 0.736 
Housewife -5.6 ±6   
-7.6 
±5   
1.6 
±2   
0.9 
±1   
-11 
±16   
-24 
±18   
0.6 
±3   0.0 ±1   
-1.3 
±4   
-1.2 
±2   
Other 6.4 ±17   
-2.2 
±10   
-0.5 
±1   
0.2 
±0   
-13 
±54   
23 
±49   
-0.7 
±7   1.8 ±2   
-1.5 
±4   
-1.3 
±2   
Children                                         
0 -4.4 ±8 0.854 
-3.6 
±8 0.531 
0.7 
±1 0.602 
0.9 
±1 0.701 
-30 
±31 0.435 
-14 
±17 0.959 
-0.9 
±3 0.224 0.1 ±2 0.304 
-1.7 
±4 0.370 
-0.1 
±2 0.706 
1 or more  -3.8 ±11   
-5.5 
±9   
1.0 
±2   
1.1 
±2   
-18 
±35 
 -15 
±35   
0.6 
±3   1.1 ±3   
-0.4 
±4 
 -0.5 
±3   
BMI (kg/m²) r 0.01 0.961 r 0.11 0.359 r 0.06 0.620 r -0.03 0.809 r -0.02 0.891 
r -
0.04 0.760 
r -
0.08  0.480 
r -
0.166 0.154 r 0.02 0.869 
r -
0.08 0.483 
Comorbidities                                         
yes -4.5 ±9 0.415 
-3.6 
±10 0.289 
0.9 
±2 0.814 
1.3 
±2 0.458 -4 ±27 0.007 
-20 
±27 0.107 
0.5 
±3 0.823 1 ±3 0.979 0.2 ±4 0.167 
-0.1 
±3 0.579 
no -2.5 ±12   
-6.0 
±9   
1.0 
±1   
1.0 
±1   
-28 
±35   
-5 
±43   
0.3 
±5   1 ±3   -1 ±4   
-0.6 
±3   
Gene mutation                                         
Negative -6.7 ±14 0.854 
-7.5 
±12 0.870 
1.9 
±2 0.357 
1.4 
±1 0.913 
-13 
±14 0.130 
-5 
±15 0.722 
1.8 
±2 0.713 0.7 ±1 0.319 0.5 ±2 0.838 
0.3 
±2 0.549 
Unknown -2.5 ±7   
-6.7 
±6   
0.8 
±1   
1.1 
±1   -92 ±0   
-39 
±10   
-0.4 
±2   0 ±1   1 ±4   
-0.3 
±3   
BRCA1 -3.2 ±11   
-4.6 
±8   
1.0 
±2   
1.1 
±2   
-16 
±33   
-14 
±40   
0.4 
±4   0.6 ±2   
-0.8 
±4   
-0.9 
±3   
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BRCA2 -4.5 ±9   
-5.4 
±11   
0.6 
±1   
0.9 
±2   
-25 
±36   
-16 
±27   
0.2 
±3   1.9 ±4   
-0.4 
±4   
0.1  
±3   
Oral contraceptive before 
surgery                                         
  yes -4.5 ±15 0.858 
-2.8 
±10 0.389 
1.0 
±2 0.982 
1.0 
±2 0.819 
-17 
±34 0.842 
-4 
±23 0.418 0 ±6 0.738 0.4 ±2 0.555 
-0.7 
±4 0.930 0 ±2 0.643 
  no -3.8 ±10   
-5.6 
±9   
0.9 
±2   
1.0 
±1   
-20 
±34   
-16 
±35   
0.5 
±3   1.1 ±3   
-0.6 
±4   
-0.5 
±3   
Regular menses                                         
  yes -6.2 ±12 0.031 
-7.3 
±10 0.031 
1.2 
±1 0.172 
1.6 
±1 0.004 
-26 
±33 0.192 
-20 
±31 0.167 1 ±4 0.118 1.7 ±4 0.018 
-0.3 
±4 0.507 
-0.2 
±3 0.540 
  no -1.2 ±7   
-2.9 
±7   
0.7 
±2   
0.5 
±1   
-14 
±34   
-8 
±36   
-0.2 
±2   0.2 ±2   
-0.9 
±4   
-0.7 
±3   
History of Breast cancer                                          
  yes -3.0 ±10 0.657 
-3.3 
±10 0.285 
0.8 
±2 0.600 
1.0 
±2 0.823 -3 ±29 0.009 
-6 
±47 0.223 
0.5 
±3 0.892 0.8 ±3 0.800 0.5 ±3 0.096 
-0.2 
±4 0.688 
  no -4.2 ±11   
-5.9 
±9   1 ±2   
1.1 
±2   
-27 
±34   
-18 
±27   
0.4 
±4   1.0 ±3   
-1.1 
±3   
-0.5 
±3   
Radiotherapy for breast 
cancer                                         
  yes -1.5 ±11 0.360 
-5.9 
±9 0.112 
0.5 
±2 0.287 
0.5 
±2 0.175 2 ±36 0.017 1 ±63 0.120 
-0.2 
±2 0.512 1.2 ±4 0.805 
-0.9 
±4 0.182 
0.7 
±3 0.237 
  no -4.3 ±10   
-1.1 
±10   1 ±2   
1.2 
±2   
-25 
±32   
-18 
±25   
0.5 
±4   1.0 ±3   0.7 ±3   
-0.6 
±3   
Chemotherapy for breast 
cancer                                         
  yes -1.8 ±11 0.407 
-1.9 
±11 0.156 
0.4 
±2 0.157 
0.8 
±2 0.423 
-0,4 
±35 0.019 
13 
±42 0.002 
0.1 
±3 0.679 
-0.3 
±2 0.109 
-0.9 
±4 0.180 
-0.3 
±3 0.567 
  no -4.3 ±10   
-5.9 
±8   
1.1 
±2   
1.1 
±2   
-25 
±32   
-21 
±29   
0.5 
±3   1.2 ±3   0.6 ±3   
-0.9 
±4   
Hormonal therapy for breast 
cancer                                         
  yes 2.7 ±8 0.263 3.5 ±10 0.083 
-0.3 
±1 0.149 
-0.2 
±2 0.132 
23 
±35 0.022 
35 
±51 0.008 
-1.7 
±3 0.283 
-0.7 
±5 0.319 0 ±3 0.785 
-1.3 
±3 0.594 
  no -4.1 ±10   
-5.6 
±9   
1.0 
±2   
1.1 
±1   
-22 
±33   
-17 
±31   
0.5 
±3   1.1 ±3   
-0.6 
±4   
-0.4 
±3   
Tamoxifen                                         
  yes 1.5 ±7 0.288 3.5 ±10 0.083 
-0.3 
±1 0.116 
-0.2 
±2 0.132 
16 
±32 0.030 
35 
±51 0.008 -1 ±3 0.397 
-0.7 
±5 0.319 
-0.5 
±3 0.961 
-1.3 
±3 0.594 
  no -4.1 ±10   
-5.6 
±9   1 ±2   
1.1 
±1   
-22 
±33   
-17 
±31   
0.5 
±3   1.1 ±3   
-0.6 
±4   
-0.4 
±3   
AMH level µg/l                                         
     (≤0.10) (N=36) -3 ±11 0.804 -3 ±9 0.161 1 ±2 0.643 1 ±2 0.798 -11 ±30 0.202 
-9 
±37 0.579 2 ±4 0.301 1 ±3 0.161 0 ±3 0.513 0 ±3 0.052 
     (0.10-1.00) (N=32) -4 ±10   -5 ±9   1 ±1   1 ±1   -25 ±38   
-19 
±34   0 ±2   0 ±1   -1 ±5   -1 ±3   
     (≥1.00) (N=23) -5 ±11   -8 ±9   1 ±2   1 ±1   -29 ±33   
-17 
±29   0 ±5   2 ±4   -1 ±4   0 ±3   
Pearson correlation indicated by r; bold indicates P<0.10; continuous variables as mean (±standard deviation); discrete variables as number (percentage). Abbreviations: SD 
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standard deviation; BC breast cancer; AMH Anti-Müllerian hormone; SFQ sexual functioning questionnaire; HADS hospital anxiety and depression scale; HFRS hot flush 
rating scale; FACT-ES functional assessment of cancer therapy – endocrine symptoms 
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Table 3 Complete mulitvariable analysis of factors associated with dependent variables  
Change at 6 weeks 
Regression 
coefficient 
(β) (95% 
CI) 
Standa
rd 
error 
P 
value 
Semipartial 
correlation  
Total 
R2 Change at 7 months 
Regression 
coefficient 
(β) (95% 
CI) 
Standa
rd 
error 
P 
value 
Semipartial 
correlation  
Total 
R2 
FACT-ES        0.143 FACT-ES        0.148 
Stable relationship 
(married/cohabitating) 
-6 (-13 to -
0.1) 3 0.046 -0.22  
Stable relationship 
(married/cohabitating) 
-5 (-11 to 
0.3) 3 0.062 -0.21   
Employment      Regular mensis (yes vs no) -4 (-8 to 0.6) 2 0.089 -0.19   
  Other ref      
Hormonal therapy for BC (yes 
vs no) 7 (-3 to 17) 5 0.175 0.15   
  Working -6 (-13 to 2) 4 0.122 -0.17   AMH ≤0.10 µg/L ref         
  Housewife -8 (-19 to 3) 6 0.175 -0.15   AMH 0.10-1.00 µg/L -1 (-5 to 4) 2 0.786 -0.03   
Regular menses (yes vs no) 
-6 (-11 to -
1.2) 2 0.015 -0.27   AMH ≥1.00 µg/L -3 (-8 to 2) 3 0.275 -0.12   
AMH ≤0.10 µg/L ref                  
AMH 0.10-1.00 µg/L 1 (-4 to 7) 3 0.622 0.05           
AMH ≥1.00 µg/L 0.4 (-6 to 7) 3 0.885 0.02           
                    
HFRS         0.06 HFRS         0.171 
Employment      Regular mensis (yes vs no) 
1.3 (0.6 to 
2.1) 0.4 0.001 0.09   
  Other ref      AMH ≤0.10 µg/L ref         
  Working 
1,0 (-0.2 to 
2.1) 1 0.111 0.19   AMH 0.10-1.00 µg/L 
-0.5 (-1.4 to 
0.3) 0.4 0.207 -0.15   
  Housewife 
1.5 (-0.3 to 
3.2) 1 0.104 0.20   AMH ≥1.00 µg/L 
-0.9 (-1.9 to 
0.0) 0.5 0.057 -0.22   
AMH ≤0.10 µg/L ref                
AMH 0.10-1.00 µg/L 
-0.5 (-1.3 to 
0.4) 0.4 0.299 -0.12          
AMH ≥1.00 µg/L 
-0.3 (-1.2 to 
0.7) 0.5 0.591 -0.06          
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SFQ         0.219 SFQ         0.348 
Education  18 (-3 to 39) 10 0.088 0.21  Age (years) 
-1 (-2.9 to 
0.8) 0.9 0.269 -0.13   
History of BC (yes vs no) 4 (-31 to 39) 18 0.818 0.03   
Stable relationship 
(married/cohabitating) 25 (-4 to 54) 15 0.094 0.20   
Radiotherapy for BC (yes vs no) 4 (-30 to 37) 17 0.834 0.03   Employment           
Chemotherapy for BC (yes vs 
no) 4 (-32 to 41) 18 0.817 0.03     Other ref         
Hormonal therapy for BC (yes 
vs no) 7 (-75 to 88) 41 0.870 0.02     Working 
-19 (-44 to 
6) 13 0.137 -0.17   
Tamoxifen (yes vs no) 
29 (-47 to 
105) 38 0.441 0.10     Housewife 
-28 (-66 to 
9) 19 0.133 -0.18   
AMH ≤0.10 µg/L ref         
Chemotherapy for BC (yes vs 
no) 23 (1 to 45) 11 0.041 0.24   
AMH 0.10-1.00 µg/L 
-11 (-32 to 
10) 10 0.278 -0.14   
Hormonal therapy for BC (yes 
vs no) 36 ('-1 to 74) 19 0.057 0.22   
AMH ≥1.00 µg/L 
-16 (-42 to 
10) 13 0.229 -0.15   AMH ≤0.10 µg/L ref         
       AMH 0.10-1.00 µg/L 
-9 (-29 to 
12) 10 0.406 -0.10   
HADS Depression         0.078 AMH ≥1.00 µg/L 
-7 (-32 to 
18) 12 0.585 -0.06   
Stable relationship 
(married/cohabitating) 
2.1 (-0.1 to 
4.3) 1 0.060 0.22          
AMH ≤0.10 µg/L ref         HADS Depression         0.132 
AMH 0.10-1.00 µg/L 
-1.4 (-3 to 
0.3) 1 0.107 -0.18   Regular menses (yes vs no) 
1.7 (0.4 to 
3.1) 0.7 0.012 0.29   
AMH ≥1.00 µg/L 
-1.1 (-3 to 
0.8) 1 0.251 -0.13   AMH ≤0.10 µg/L ref        
       AMH 0.10-1.00 µg/L 
-1.3 (-3 to 
0.2) 1 0.094 -0.19   
HADS Anxiety         0.092 AMH ≥1.00 µg/L 
0.3 (-1.4 to 
2.0) 1 0.730 0.04   
Stable relationship 
(married/cohabitating) 
2.3 (-0.06 to 
4.6) 1 0.056 0.22          
History of BC (yes vs no) 
1.5 (-0.5 to 
3.5) 1 0.148 0.17   HADS Anxiety     0.080 
AMH ≤0.10 µg/L ref         AMH ≤0.10 µg/L ref         
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AMH 0.10-1.00 µg/L -0.8 (-3 to 1) 1 0.459 -0.08   AMH 0.10-1.00 µg/L 
-1.5 (-3 to 
0.1) 1 0.060 -0.22   
AMH ≥1.00 µg/L -0.4 ('-3 to 2) 1 0.755 -0.04   AMH ≥1.00 µg/L 
0.4 (-1.3 to 
2.2) 1 0.618 0.06   
Bold indicates statistical significance, P < 0.05. CI = Confidence interval, SD = standard deviation, SFQ = sexual functioning questionnaire, HADS = hospital anxiety and depression scale, 
HFRS = hot flush rating scale, FACT-ES = functional assessment cancer treatment - endocrine symptoms, AMH = Anti-Müllerian hormone, BC = breast cancer 
 
